Literature DB >> 11724078

Pharmacokinetics of para-aminosalicylic acid granules under four dosing conditions.

C A Peloquin1, M Zhu, R D Adam, M D Singleton, D E Nix.   

Abstract

OBJECTIVE: To determine the pharmacokinetics and relative bioavailability of para-aminosalicylic acid (PAS) granules.
DESIGN: Phase I pharmacokinetics study.
SETTING: University of Arizona School of Pharmacy. PARTICIPANTS: Sixteen healthy male and female volunteers aged 36 +/- 8 years.
INTERVENTIONS: Subjects received single doses of PAS granules (6 g) combined with cycloserine 500 mg, clofazimine 200 mg, ethionamide 500 mg, and pyridoxine 100 mg. Drugs were given on an empty stomach after an overnight fast (reference) with high-fat food, with orange juice, and with antacids. MEASUREMENTS AND
RESULTS: Four subjects did not complete all four treatments due to adverse events or personal reasons. Plasma and urine samples were collected for 48 hours and measured by a validated HPLC assay. Pharmacokinetic data analysis was performed with WinNonlin using noncompartmental methods and a one-compartmental model. Bioequivalence testing was performed using the mean ratios of the maximum concentrations (Cmax) and AUC(0-infinity) of PAS, with 90% confidence intervals. Compared with the fasted condition, food increased Cmax 1.5-fold and AUC(0-infinity) 1.7-fold, and it doubled the time to maximum concentration (tmax). The least-squares mean ratios (treatment/reference) for Cmax were 0.90 (58% to 139% CI), 1.16 (75% to 179% CI), and 0.82 (52% to 127% CI) with orange juice, food, or antacid treatment, respectively. Corresponding ratios for AUC(0-infinity) were 1.05 (71% to 155% CI), 1.52 (103% to 224% CI), and 0.84 (57% to 125% CI), respectively.
CONCLUSIONS: Food significantly enhanced the absorption of PAS, while orange juice and antacids had minor effects.

Entities:  

Mesh:

Substances:

Year:  2001        PMID: 11724078     DOI: 10.1345/aph.1A088

Source DB:  PubMed          Journal:  Ann Pharmacother        ISSN: 1060-0280            Impact factor:   3.154


  15 in total

Review 1.  The pharmacokinetics of para-aminosalicylic acid and its relationship to efficacy and intolerance.

Authors:  Ahmed A Abulfathi; Peter R Donald; Kim Adams; Elin M Svensson; Andreas H Diacon; Helmuth Reuter
Journal:  Br J Clin Pharmacol       Date:  2020-06-21       Impact factor: 4.335

Review 2.  Revisiting the mutant prevention concentration to guide dosing in childhood tuberculosis.

Authors:  Devan Jaganath; H Simon Schaaf; Peter R Donald
Journal:  J Antimicrob Chemother       Date:  2017-07-01       Impact factor: 5.790

Review 3.  Clinically significant drug interactions with antacids: an update.

Authors:  Ryuichi Ogawa; Hirotoshi Echizen
Journal:  Drugs       Date:  2011-10-01       Impact factor: 9.546

4.  Pharmacokinetics of para-aminosalicylic acid in HIV-uninfected and HIV-coinfected tuberculosis patients receiving antiretroviral therapy, managed for multidrug-resistant and extensively drug-resistant tuberculosis.

Authors:  Lizanne de Kock; Sherwin K B Sy; Bernd Rosenkranz; Andreas H Diacon; Kim Prescott; Kenneth R Hernandez; Mingming Yu; Hartmut Derendorf; Peter R Donald
Journal:  Antimicrob Agents Chemother       Date:  2014-08-11       Impact factor: 5.191

Review 5.  Therapeutic drug monitoring in the treatment of tuberculosis.

Authors:  Charles A Peloquin
Journal:  Drugs       Date:  2002       Impact factor: 9.546

6.  N-acetyltransferase genotypes and the pharmacokinetics and tolerability of para-aminosalicylic acid in patients with drug-resistant pulmonary tuberculosis.

Authors:  Sherwin K B Sy; Lizanne de Kock; Andreas H Diacon; Cedric J Werely; Huiming Xia; Bernd Rosenkranz; Lize van der Merwe; Peter R Donald
Journal:  Antimicrob Agents Chemother       Date:  2015-05-11       Impact factor: 5.191

7.  Dose regimen of para-aminosalicylic acid gastro-resistant formulation (PAS-GR) in multidrug-resistant tuberculosis.

Authors:  Yves Kibleur; Hervé Brochart; Hendrik S Schaaf; Andre H Diacon; Peter R Donald
Journal:  Clin Drug Investig       Date:  2014-04       Impact factor: 2.859

8.  HPLC analysis of para-aminosalicylic acid and its metabolite in plasma, cerebrospinal fluid and brain tissues.

Authors:  Lan Hong; Wendy Jiang; Wei Zheng; Su Zeng
Journal:  J Pharm Biomed Anal       Date:  2010-11-27       Impact factor: 3.935

9.  Evaluation of para-Aminosalicylic Acid as a Substrate of Multiple Solute Carrier Uptake Transporters and Possible Drug Interactions with Nonsteroidal Anti-inflammatory Drugs In Vitro.

Authors:  M Masud Parvez; Ho Jung Shin; Jin Ah Jung; Jae-Gook Shin
Journal:  Antimicrob Agents Chemother       Date:  2017-04-24       Impact factor: 5.191

10.  Chelation therapy of manganese intoxication with para-aminosalicylic acid (PAS) in Sprague-Dawley rats.

Authors:  Wei Zheng; Yue-Ming Jiang; Yanshu Zhang; Wendy Jiang; Xueqian Wang; Dallas M Cowan
Journal:  Neurotoxicology       Date:  2008-12-25       Impact factor: 4.294

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.